Last reviewed · How we verify
Probucol group
Probucol is a lipophilic antioxidant that reduces cholesterol levels and prevents LDL oxidation.
Probucol is a lipophilic antioxidant that reduces cholesterol levels and prevents LDL oxidation. Used for Hypercholesterolemia, Atherosclerosis prevention.
At a glance
| Generic name | Probucol group |
|---|---|
| Also known as | Changtai |
| Sponsor | Otsuka Beijing Research Institute |
| Drug class | Antioxidant lipid-lowering agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Probucol lowers serum cholesterol through inhibition of cholesterol synthesis and increased fecal excretion of cholesterol and bile acids. It also acts as a potent antioxidant, preventing the oxidation of low-density lipoprotein (LDL), which is thought to reduce atherosclerosis progression and improve endothelial function.
Approved indications
- Hypercholesterolemia
- Atherosclerosis prevention
Common side effects
- QT prolongation
- Gastrointestinal disturbances
- Xanthomas regression
Key clinical trials
- Expanded Access Program for R007 (Probucol) Tablets in Adults With Mitochondrial Disease and Chronic Kidney Disease
- Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker (PHASE4)
- Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke
- The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques (PHASE4)
- Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis (PHASE3)
- Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety (PHASE2)
- Pharmacokinetics Study for Probucol (PHASE4)
- Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Probucol group CI brief — competitive landscape report
- Probucol group updates RSS · CI watch RSS
- Otsuka Beijing Research Institute portfolio CI